Top Markets
#1 PulseChain PulseChain +48.38%
#2 Ergo Ergo +22.78%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +17.06%
#4 RedStone RedStone +15.48%
#5 SkyAI SkyAI +11.00%
#6 Lighter Lighter +9.58%
#7 MarsCoin MarsCoin +9.07%
#8 OPENLOOT OPENLOOT +8.87%
#9 Monad Monad +8.43%
#10 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.93%
Coin of the day
PulseChain PulseChain
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Angion Biomedica Corp. Angion Biomedica Corp.

Angion Biomedica Corp.

ANGN
Rangering i aksjer #27858
Angion Biomedica Corp. operates as a biopharmaceutical enterprise,... Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.
Aksjekurs
$1.00
Sist synkronisert: 2023-06-01
Markedsverdi
$30.11M
Endring (1 dag)
2.04%
Endring (1 år)
0.00%
Land
US
Handel Angion Biomedica Corp. (ANGN)

Kategori

Healthcare
Inntekter for Angion Biomedica Corp. (ANGN)
Inntekter i 2026 TTM: 0
Ifølge Angion Biomedica Corp. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Angion Biomedica Corp. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH